• Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab

  • Jul 15 2024
  • Length: 9 mins
  • Podcast

Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab By cover art

Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab

Listen for free

View show details

  • Summary

  • Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss recent data analyzing the real-world implications of donanemab treatment for people with Alzheimer disease.
    Show more Show less
activate_primeday_promo_in_buybox_DT
Physical Illness & Disease Hygiene & Healthy Living Biological Sciences
Show more Show less

What listeners say about Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available